

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILI	NG DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/383,579	08/25/1999		MICHAEL MEYRICK BURRELL	9341-018-999	6768
7	590	09/24/2003			
David A. Jackson				EXAMINER	
Klauber & Jackson 411 Hackensack Avenue				BAUM, STUART F	UART F
Hackensack, N	J 07601			ART UNIT PAPER NUMBER	
				1638	1-
•				DATE MAILED: 09/24/2003	1

Please find below and/or attached an Office communication concerning this application or proceeding.

* *	Application No.	Applicant(s)						
Office Action Summary	09/383,579	BURRELL ET AL.						
Office Action Summary	Examiner	Art Unit						
The MAILING DATE of this communication app	Stuart F. Baum	1638						
Period for Reply	lears on the cover sin	see with the correspondence address						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, y within the statutory minimum will apply and will expire SIX (i, cause the application to bec	may a reply be timely filed of thirty (30) days will be considered timely. 3) MONTHS from the mailing date of this communication. ome ABANDONED (35 U.S.C. § 133).						
1) Responsive to communication(s) filed on 30 J	<u>lune 2003</u> .							
2a) This action is FINAL . 2b) ⊠ Th	is action is non-final.							
3) Since this application is in condition for allowed closed in accordance with the practice under a secondary.								
Disposition of Claims	Ex parte Quayle, 190	55 C.D. 11, 455 C.G. 215.						
4)⊠ Claim(s) <u>19-36</u> is/are pending in the applicatio	on.							
4a) Of the above claim(s) is/are withdraw	4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.	Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.	Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.	Claim(s) is/are objected to.							
8)⊠ Claim(s) <u>19-36</u> are subject to restriction and/or	election requiremen	t.						
Application Papers								
9) The specification is objected to by the Examine		hudha Funninan						
10) The drawing(s) filed on is/are: a) acception acception acception acception to the Applicant may not request that any objection to the								
11) The proposed drawing correction filed on								
If approved, corrected drawings are required in rep								
12) The oath or declaration is objected to by the Ex								
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign	n priority under 35 U.	S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:								
1. Certified copies of the priority documents								
2. Certified copies of the priority documents	2. Certified copies of the priority documents have been received in Application No							
 3. Copies of the certified copies of the prior application from the International But * See the attached detailed Office action for a list 	reau (PCT Rule 17.2	(a)).						
14) Acknowledgment is made of a claim for domestic	c priority under 35 U	S.C. § 119(e) (to a provisional application).						
 a) The translation of the foreign language pro 15) Acknowledgment is made of a claim for domesting 	, ,							
Attachment(s)								
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 Not	erview Summary (PTO-413) Paper No(s) ice of Informal Patent Application (PTO-152) er:						

Application/Control Number: 09/383,579 Page 2

Art Unit: 1638

DETAILED ACTION

1. The amendment filed 6/30/2003 has been entered.

Claims 19-36 are pending.

Claims 1-18 have been canceled.

Claims 19-36 have been newly submitted.

2. In view of the cancellation of all of the previously restricted claims and the newly submitted claims, a supplemental restriction is warranted. Applicant has elected with traverse the claims of Group I. It is noted that Applicant has not elected a sequence even though the restriction mailed 3/26/2003 required Applicant to elect one sequence from a list.

Objection is made to claim 1 which specifies a DNA sequence by the term Ex29. 37

CFR 1.821(d) requires the use of the assigned sequence identifier (e.g. SEQ I.D. NO: X) in all instances where the description or claims of a patent application discuss sequences.

Election/Restrictions

4. Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 19-23, 31, and 34-36, drawn to a method of transforming trees to modify the fibre characteristics in trees comprising transforming said plant with any chimeric gene comprising a promoter operably linked to a nucleic acid sequence in sense orientation encoding an expansin capable of modifying at least one of:

Application/Control Number: 09/383,579

Art Unit: 1638

fiber cell wall extension, tree height or internode length, classified in class 800, subclass 290 for example.

Page 3

II. Claims 19 and 22, drawn to a method of transforming trees to modify the fibre characteristics in trees comprising transforming said plant with any chimeric gene comprising a promoter operably linked to a nucleic acid sequence in antisense orientation wherein said sequence is capable of modifying at least one of: fiber cell wall extension, tree height or internode length, classified in class 800, subclass 290 for example.

III. Claims 24-30, and 32-33, drawn to a nucleic acid sequence and chimeric gene comprising said nucleic acid sequence, classified in class 536, subclass 23.1 for example.

For the election to be complete, Applicant is required to elect one sequence from the following list and to specify if the sequence is from *Eucalyptus* or cucumber:

SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEO ID NO:4; SEO ID NO:5; SEO ID NO:6.

- 5. Inventions I through III are unrelated to each other. The method of transforming a tree to modify fiber characteristic of Group I does not require the antisense molecules associated with the method of Group II.
- 6. Inventions I-II, and III are unrelated to each other. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the

Application/Control Number: 09/383,579 Page 4

Art Unit: 1638

instant case the different inventions are distinct because the starting materials, methods steps and end products are distinct and unrelated to each other. Examples of divergent method steps are the specific temporal, spatial and quantitative expression patterns required to modify fiber characteristics which are different than the expression patterns associated with plant transformation of Group III.

- 7. Sequences 1-6 are unrelated to each other. Applicant is reminded that nucleotide sequences either encoding different proteins or specifying specific expression patterns are structurally distinct chemical compounds and are unrelated to one another, as are different proteins structurally distinct chemical compounds and unrelated to one another. These sequences are thus deemed to normally constitute **independent and distinct** inventions within the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq (see MPEP 803.04 and 2434). This requirement is not to be construed as a requirement for an election of species, since each nucleotide and amino acid sequence is not a member of a single genus of invention, but constitutes an independent and patentably distinct invention.
- 8. Because these inventions are distinct for the reasons given above, have acquired a separate status in the art as shown by their different classification, and the literature and sequence searches required for each of the Groups are not required for another of the Groups, restriction for examination purposes as indicated is proper.

Application/Control Number: 09/383,579

Page 5

Art Unit: 1638

9. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37

CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the 10. inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

application. Any amendment of inventorship must be accompanied by a petition under 37

CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the 11.

examiner should be directed to Stuart F. Baum whose telephone number is 703-305-6997. The

examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Amy Nelson can be reached on 703-306-3218. The fax phone number for the

organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is 703-308-0196.

Stuart F. Baum Ph.D.

September 17, 2003